Amgen Inc. $AMGN Shares Sold by Trilogy Capital Inc.

Trilogy Capital Inc. cut its holdings in Amgen Inc. (NASDAQ:AMGN) by 2.6% during the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 10,717 shares of the medical research company’s stock after selling 285 shares during the period. Trilogy Capital Inc.’s holdings in Amgen were worth $2,992,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also made changes to their positions in the company. Brighton Jones LLC raised its position in shares of Amgen by 23.5% during the 4th quarter. Brighton Jones LLC now owns 27,468 shares of the medical research company’s stock worth $7,159,000 after purchasing an additional 5,226 shares during the last quarter. NBC Securities Inc. raised its position in shares of Amgen by 111,133.3% during the 1st quarter. NBC Securities Inc. now owns 6,674 shares of the medical research company’s stock worth $2,079,000 after purchasing an additional 6,668 shares during the last quarter. Vantage Wealth raised its position in shares of Amgen by 4.2% during the 1st quarter. Vantage Wealth now owns 69,614 shares of the medical research company’s stock worth $21,688,000 after purchasing an additional 2,813 shares during the last quarter. Merit Financial Group LLC raised its holdings in Amgen by 8.6% in the 1st quarter. Merit Financial Group LLC now owns 20,252 shares of the medical research company’s stock valued at $6,309,000 after acquiring an additional 1,609 shares during the last quarter. Finally, HBW Advisory Services LLC raised its holdings in Amgen by 10.8% in the 1st quarter. HBW Advisory Services LLC now owns 9,484 shares of the medical research company’s stock valued at $2,955,000 after acquiring an additional 925 shares during the last quarter. Institutional investors and hedge funds own 76.50% of the company’s stock.

Amgen Price Performance

AMGN opened at $282.20 on Wednesday. The firm has a market cap of $151.93 billion, a price-to-earnings ratio of 23.07, a price-to-earnings-growth ratio of 2.38 and a beta of 0.49. Amgen Inc. has a fifty-two week low of $253.30 and a fifty-two week high of $335.88. The company’s 50-day moving average price is $287.95 and its 200 day moving average price is $288.57. The company has a quick ratio of 0.98, a current ratio of 1.31 and a debt-to-equity ratio of 7.24.

Amgen (NASDAQ:AMGN) last released its quarterly earnings data on Tuesday, August 5th. The medical research company reported $6.02 earnings per share for the quarter, topping the consensus estimate of $5.28 by $0.74. The firm had revenue of $9.18 billion for the quarter, compared to analyst estimates of $8.86 billion. Amgen had a net margin of 18.96% and a return on equity of 174.71%. Amgen’s quarterly revenue was up 9.4% on a year-over-year basis. During the same quarter in the prior year, the business earned $4.97 earnings per share. Amgen has set its FY 2025 guidance at 20.200-21.300 EPS. As a group, sell-side analysts expect that Amgen Inc. will post 20.62 earnings per share for the current year.

Amgen Dividend Announcement

The company also recently announced a quarterly dividend, which was paid on Friday, September 12th. Shareholders of record on Friday, August 22nd were given a $2.38 dividend. The ex-dividend date was Friday, August 22nd. This represents a $9.52 annualized dividend and a yield of 3.4%. Amgen’s dividend payout ratio is 77.84%.

Analyst Upgrades and Downgrades

Several analysts have recently issued reports on AMGN shares. Wall Street Zen cut shares of Amgen from a “buy” rating to a “hold” rating in a research note on Saturday, August 9th. Piper Sandler upped their price objective on shares of Amgen from $328.00 to $342.00 and gave the company an “overweight” rating in a research report on Monday, August 25th. UBS Group decreased their price objective on shares of Amgen from $326.00 to $317.00 and set a “neutral” rating for the company in a research report on Wednesday, August 6th. Morgan Stanley upped their price objective on shares of Amgen from $330.00 to $333.00 and gave the company an “equal weight” rating in a research report on Wednesday, August 6th. Finally, William Blair restated an “outperform” rating on shares of Amgen in a research note on Tuesday, June 24th. Seven analysts have rated the stock with a Buy rating, twelve have assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, the stock presently has an average rating of “Hold” and an average target price of $309.70.

Insider Buying and Selling

In other Amgen news, SVP Nancy A. Grygiel sold 1,267 shares of the company’s stock in a transaction dated Wednesday, August 20th. The shares were sold at an average price of $296.99, for a total value of $376,286.33. Following the completion of the transaction, the senior vice president owned 7,209 shares in the company, valued at approximately $2,141,000.91. This represents a 14.95% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Company insiders own 0.69% of the company’s stock.

About Amgen

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.